… CAR-T cell outcomes in patients with comorbidities …

… Thrombotic microangiopathy (TMA) after CAR-T cell therapy …

… piece of artwork from patients recovered through CAR-T cell therapy. We then get to hear a panel discussion from … with CRS and ICANS in DLBCL patients undergoing CAR-T cell therapy. Key messages: standardise hospital practices, … as well as learning about treosulfan-based conditioning, CAR-T cell therapy and toxicities, and haematopoietic stem …

… collaborations across stakeholders in the field of CAR T-cell therapies. The selection committee was composed by … on the feasibility, safety and efficacy of anti-CD19 CAR-T cells in acute lymphoblastic leukemia ” (co-PIs: …

… discussed infusion strategies, comparing stem cells, CAR-T, and lymphocytes. This talk aimed to underline the … and non-malignant patients. She also presented figures on CAR-T therapy in children and gene therapy trials, noting …

… too early to talk about responses. Among all abstracts on CAR-T cells in AML, THINK trial, a phase I trial on NKG2D where … moving to the upfront setting, BiTes and most importantly CAR-T cells. These therapeutic waves may render myeloma a …

… allogeneic and autologous transplantations, as well as CAR-T cell therapy. I am honoured to work alongside other …

… (HCT) in myelodysplastic syndromes (MDS) and HCT and CAR-T in autoimmune diseases (ADs). Carmelo Gurnari reviewed the … the session by discussing recent recommendations on CAR-T cell therapies in autoimmune diseases. She highlighted …

… maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, allowed deep and durable responses in … of ide-cel resistance. Besides, other BCMA-directed CAR-T products, such as ciltacabtagene autoleucel, have …

… cured) with an autologous transplant. The introduction of CAR-T can further muddle the waters in the future. At the moment, … to support a better cure rate for patients with FL with CAR-T than with autologous transplant, contrasting with the …